LeonaBio CMO San Martin Javier Receives 350,000-Share Award

What Happened

• San Martin Javier, Chief Medical Officer of LeonaBio (LONA), received a grant of 350,000 derivative shares (reported as an award/option) on 2026-04-09. The filing reports an acquisition amount of $0.00 for the grant (i.e., an equity award/option grant rather than an open-market purchase).

Key Details

• Transaction date: 2026-04-09. Form 4 filed: 2026-04-13 (timely filing).
• Transaction type/code: A — Award/Grant of derivative security (option); reported acquisition price $0.00.
• Shares subject to grant: 350,000.
• Shares owned after transaction: Not specified in this filing.
• Footnote: The award vests monthly over 48 months on the monthly anniversaries of the grant date, contingent on continued service under the Issuer’s 2026 Equity Incentive Plan.

Context

• This is an equity award/option grant, not a cash purchase or sale. The grant does not represent immediate cash value until (and unless) options vest and are exercised; future value depends on LeonaBio’s stock price and any exercise price/terms. Such grants are common for executive compensation and do not by themselves indicate immediate insider buying or selling.